Pleural Mesothelioma Clinical Trial
— SCITH-MESOOfficial title:
Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is a rare pleural cancer, which could be primary or secondary to an asbestos exposure. To enhance our knowledge of this rare disease, an exploration of genetic and tumor mechanism is mandatory. One of the principal difficulty is to harvest sufficient tumour pieces to perform multi-omics analysis. The goal of the SCITH-MESO study is to harvest larges pieces of tumour during a routine surgical procedure of MPM diagnosis by mean of pleural biopsies during VATS surgery. Operating samples will increase a tissue bank collection (CRB).
Status | Recruiting |
Enrollment | 30 |
Est. completion date | February 11, 2026 |
Est. primary completion date | February 11, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 95 Years |
Eligibility | Inclusion Criteria: - age >18 - suspected MPM requiring VATS biopsy after multidisciplinary oncologic board validation - patient able to understand study objectives and able to give an informed consent - patient affiliated to an healthcare society. Exclusion Criteria: - pregnancy - mental disease, psychiatric disorder - patient under protection regimen |
Country | Name | City | State |
---|---|---|---|
France | Département de chirurgie thoracique | Bron |
Lead Sponsor | Collaborator |
---|---|
Hospices Civils de Lyon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | For patients with MPM, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques). | For patients with MPM, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques). | day 1 (day of chirurgie) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04914897 -
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
|
Phase 2 | |
Recruiting |
NCT05910112 -
Prospective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention
|
||
Recruiting |
NCT02588131 -
A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)
|
Phase 2 | |
Recruiting |
NCT05930665 -
Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma
|
Phase 2 | |
Recruiting |
NCT06362369 -
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
|
Phase 1/Phase 2 | |
Completed |
NCT02414945 -
TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT05714553 -
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
Completed |
NCT02585362 -
Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program
|
N/A | |
Completed |
NCT00299962 -
Gene Therapy for Pleural Malignancies
|
Phase 1 | |
Terminated |
NCT04106973 -
Mesothelioma Early Detection by VOCs
|
||
Not yet recruiting |
NCT06155279 -
Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)
|
Phase 2 | |
Not yet recruiting |
NCT06416930 -
Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma
|
Phase 2 | |
Completed |
NCT01160458 -
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
|
Phase 2 | |
Completed |
NCT02899195 -
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
|
Phase 2 | |
Active, not recruiting |
NCT04040231 -
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
|
Phase 1 | |
Completed |
NCT04324437 -
eRAPID: Online Symptom Reporting in Lung Cancer
|
N/A | |
Completed |
NCT04430842 -
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
|
Phase 1 | |
Recruiting |
NCT03210298 -
International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
|
||
Terminated |
NCT00895648 -
Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma
|
Phase 2 |